Aditxt, Inc. (ADTX)
After hours:
| Previous close | 0.4585 |
| Open | 0.4660 |
| Bid | 0.3220 x 200 |
| Ask | 0.5518 x 200 |
| Day's range | 0.4200 - 0.4698 |
| 52-week range | 0.4160 - 24.0000 |
| Volume | |
| Avg. volume | 2,556,888 |
| Market cap | 1.613M |
| Beta (5Y monthly) | 0.98 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -34.3800 |
| Earnings date | 12 Nov 2024 - 18 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Aditxt and Evofem Sign Second Amendment to Amended and Restated Merger Agreement, Target Closing of Acquisition in Fourth Quarter of 2024
MOUNTAIN VIEW, Calif. & SAN DIEGO, September 09, 2024--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation platform dedicated to accelerating health innovations, and women’s health pioneer, Evofem Biosciences, Inc. (OTCQB: EVFM) ("Evofem") today announced they have entered into the Second Amendment to the Amended and Restated Agreement and Plan of Merger (the "Second Amendment"), under which Aditxt intends to acquire Evofem.
- Business Wire
Aditxt Subsidiary Pearsanta Submits a Grant Application Seeking to Advance Clinical Trials for Mitomic® Prostate Test, Targeting Early Detection in High-Risk Patients
MOUNTAIN VIEW, Calif., September 04, 2024--Aditxt, Inc. ("Aditxt") (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced that its subsidiary, Pearsanta, Inc. ("Pearsanta"), has submitted a grant application to the Prostate Cancer Research Program (PCRP) under the Department of Defense (DoD) Implementation Science Award funding mechanism seeking $2 million in funding. This non-dilutive funding initiative aims to advance the early det
- Business Wire
Aditxt to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 9th-11th, 2024
MOUNTAIN VIEW, Calif., August 29, 2024--Aditxt, Inc. ("Aditxt" or the "Company") (NASDAQ: ADTX), an innovation platform dedicated to discovering, developing, and deploying promising health innovations, today announced that it will present virtually and participate in one-on-one investor meetings at the H.C. Wainwright 26th Annual Global Investment Conference, taking place at the Lotte New York Palace Hotel in New York City from September 9th-11th, 2024.
